-transparent.png){kind=logo}
Imipenem is a new beta-lactam antibiotic with a wide spectrum of activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The efficacy and toxicity of this drug, when administered parenterally in combination with the dehydropeptidase I inhibitor cilastatin, were studied in 41 hospitalized patients with serious infections. Clinical cure was achieved in 26 (79%) of the 33 patients who could be evaluated and microbiologic cure in 23 (85%) of the 27 patients who could be evaluated. Adverse clinical or laboratory reactions were observed in seven (17%) of the 41 patients. Thus, imipenem/cilastatin was highly effective in the treatment of a wide variety of serious bacterial infections.
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
January 1985,
Reviews of infectious diseases,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
January 1985,
Clinical therapeutics,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
January 1985,
Reviews of infectious diseases,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
January 1991,
Clinical therapeutics,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
January 1987,
Scandinavian journal of infectious diseases. Supplementum,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
June 2000,
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
April 1984,
Lancet (London, England),
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
November 1984,
Antimicrobial agents and chemotherapy,
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
April 1990,
Presse medicale (Paris, France : 1983),
R G Brooks, and
R E McCabe, and
K L Vosti, and
J S Remington
January 1992,
Clinical therapeutics,
